Compare STRO & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRO | OPRX |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 167.1M |
| IPO Year | 2018 | 2008 |
| Metric | STRO | OPRX |
|---|---|---|
| Price | $8.76 | $7.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $44.69 | $11.90 |
| AVG Volume (30 Days) | ★ 291.0K | 210.5K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 124.55 |
| EPS | N/A | ★ N/A |
| Revenue | $38,419,000.00 | ★ $109,429,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.78 |
| 52 Week Low | $0.72 | $4.54 |
| 52 Week High | $43.85 | $15.59 |
| Indicator | STRO | OPRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.40 | 36.44 |
| Support Level | $8.11 | $6.00 |
| Resistance Level | $10.77 | $7.14 |
| Average True Range (ATR) | 0.85 | 0.76 |
| MACD | 0.14 | -0.28 |
| Stochastic Oscillator | 17.01 | 18.97 |
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.